Avadel Pharmaceuticals plc

NasdaqGM AVDL

Avadel Pharmaceuticals plc Price to Earnings Ratio (P/E) on December 30, 2024: -13.94

Avadel Pharmaceuticals plc Price to Earnings Ratio (P/E) is -13.94 on December 30, 2024, a -63.67% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Avadel Pharmaceuticals plc 52-week high Price to Earnings Ratio (P/E) is -7.18 on February 28, 2024, which is 48.47% above the current Price to Earnings Ratio (P/E).
Avadel Pharmaceuticals plc 52-week low Price to Earnings Ratio (P/E) is -21.64 on November 11, 2024, which is -55.24% below the current Price to Earnings Ratio (P/E).
Avadel Pharmaceuticals plc average Price to Earnings Ratio (P/E) for the last 52 weeks is -12.31.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqGM: AVDL

Avadel Pharmaceuticals plc

CEO	Mr. Gregory J. Divis Jr.
IPO Date	June 7, 1996
Location	Ireland
Headquarters	10 Earlsfort Terrace
Employees	154
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Key trends

Past 5 years